Wire · opportunities
Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The Barbara Ann Karmanos Cancer Institute now offers daraxonrasib (Rasonque), an FDA-approved oral therapy for adults with metastatic pancreatic adenocarcinoma who have failed prior systemic therapy or are unsuitable for multiagent systemic therapy, following positive phase III trial results showing improved survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You can now access a newly approved oral cancer drug that extends survival for metastatic pancreatic patients who failed other therapies. If your startup supports pancreatic cancer treatment or diagnostics, this approval opens avenues for collaboration and innovation.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Topics